Loading...
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
T cells redirected to specific antigen targets with engineered chimeric antigen receptors (CARs) are emerging as powerful therapies in hematologic malignancies. Various CAR designs, manufacturing processes, and study populations, among other variables, have been tested and reported in over 10 clinic...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3999751/ https://ncbi.nlm.nih.gov/pubmed/24578504 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-11-492231 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|